On Friday, Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) posted a 7.53% loss after Jefferies expressed concern about the companyâs sound usage of risk calculation for the obesity drug Lorcaserin. As of 8:34AM EDT, the biopharmaceutical company was up 2.71% to $6.81, which is at the high end of the stockâs 52-week range of $2.70-$8.00. The stock has traded 40,684 shares, with an average volume of 8.8 million shares.
-Michael B. Sauter
Comments are closedPowered By iWebRSS.com